Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination
MT Newswires Live
Oct 08
Agenus (AGEN) said Thursday that Armenia's Ministry of Health approved its combination therapy, Botvymo and Evamplix, to treat adults with a type of colorectal cancer.
The company said the approvals are conditional and valid for one year, subject to renewal based on clinical updates provided to Armenian regulators.
Under the approved regimen, Botvymo, or botensilimab, is given intravenously every six weeks for up to four doses, while Evamplix, or balstilimab, is given every two weeks for up to two years or until disease progression or unacceptable side effects, the company said.
Agenus said it will evaluate seeking approvals in other Eurasian Economic Union countries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.